论文部分内容阅读
目的探讨中国缺血性脑卒中(IS)患者抗血小板类药物的使用现状及影响用药的相关因素。方法对我国北方和中、东部14个城市的病程>3个月的IS患者的基本资料及服用抗血小板类药物的情况进行调查和分析。结果共有6422例IS患者被调查,均有服用抗血小板药物的适应证,但仅有72.4%患者(4652例)服用抗血小板药物;其中98.7%服用阿司匹林;IS≥3年的患者服药率(64.0%)明显低于IS<1年的患者(72.0%)(P<0.001);合并冠心病、高血压的患者服药率明显高于无此类合并症的患者(均P<0.001)。结论中国IS患者抗血小板药物使用现状与IS二级预防指南推荐的均应服用抗血小板药物的要求存在明显的差距,尤其是病程较长的IS患者。
Objective To investigate the current status of antiplatelet drugs used in Chinese patients with ischemic stroke (IS) and the related factors influencing medication. Methods The basic data of IS patients with disease duration> 3 months in 14 cities in the north, central and east China and the antiplatelet drugs were investigated and analyzed. RESULTS: A total of 6422 patients with IS were investigated. All received antiplatelet agents, but only 72.4% (4652 patients) took antiplatelet drugs; 98.7% received aspirin; and IS ≥ 3 years (64.0% %) Was significantly lower than those in patients with IS <1 year (72.0%) (P <0.001). Patients taking coronary heart disease and hypertension had higher medication rates than those without such complications (all P <0.001). Conclusions There is a clear gap between the current status of antiplatelet use in Chinese IS patients and the recommended antiplatelet drugs recommended by the IS secondary prevention guidelines, especially those with longer course of IS.